Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan W Friedberg

Showing results (11-20 of 300) with videos related to

Pageof 30
Sort By:
Blood|May 27, 2008
Bak to death with chemotherapyJonathan W Friedberg
Haematologica|November 4, 2006
Potential long-term toxicities should influence the choice of therapy for indolent non-Hodgkin's lymphomaJonathan W Friedberg
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2021
An Oncology RenaissanceJonathan W Friedberg
Hematology. American Society of Hematology. Education Program|November 24, 2005
Unique toxicities and resistance mechanisms associated with monoclonal antibody therapyJonathan W Friedberg
Blood|June 11, 2017
How I treat double-hit lymphomaJonathan W Friedberg
Lancet (London, England)|December 24, 2010
Rituximab maintenance in follicular lymphoma: PRIMAJonathan W Friedberg
Seminars in Hematology|September 2, 2008
Treatment of follicular non-Hodgkin's lymphoma: the old and the newJonathan W Friedberg
The Lancet. Oncology|May 2, 2006
Rituximab for early-stage diffuse large-B-cell lymphomaJonathan W Friedberg
Hematological Oncology|June 9, 2023
Update on follicular lymphomaJonathan W Friedberg
Leukemia & Lymphoma|October 9, 2009
Bendamustine in chronic lymphocytic leukemia: the future is combination therapyJonathan W Friedberg
Pageof 30

Showing results (11-20 of 300) with videos related to

Sort By:
Pageof 30
Blood|May 27, 2008
Bak to death with chemotherapyJonathan W Friedberg
Haematologica|November 4, 2006
Potential long-term toxicities should influence the choice of therapy for indolent non-Hodgkin's lymphomaJonathan W Friedberg
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2021
An Oncology RenaissanceJonathan W Friedberg
Hematology. American Society of Hematology. Education Program|November 24, 2005
Unique toxicities and resistance mechanisms associated with monoclonal antibody therapyJonathan W Friedberg
Blood|June 11, 2017
How I treat double-hit lymphomaJonathan W Friedberg
Lancet (London, England)|December 24, 2010
Rituximab maintenance in follicular lymphoma: PRIMAJonathan W Friedberg
Seminars in Hematology|September 2, 2008
Treatment of follicular non-Hodgkin's lymphoma: the old and the newJonathan W Friedberg
The Lancet. Oncology|May 2, 2006
Rituximab for early-stage diffuse large-B-cell lymphomaJonathan W Friedberg
Hematological Oncology|June 9, 2023
Update on follicular lymphomaJonathan W Friedberg
Leukemia & Lymphoma|October 9, 2009
Bendamustine in chronic lymphocytic leukemia: the future is combination therapyJonathan W Friedberg
Pageof 30